Scinai Immunotherapeutics Refocuses R&D on NanoAb Platform and CDMO Growth

Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) has announced a strategic refocusing of its research and development portfolio following the expiration and termination of its option and license arrangements with PinCell S.r.l. related to PC111. The decision, effective Aug. 31, was not driven by any new negative scientific findings regarding PC111, according to the company. Instead, it allows Scinai to concentrate its R&D resources on its NanoAb platform while preserving capital and management capacity for its contract development and manufacturing organization (CDMO) business.

This move underscores Scinai's commitment to advancing its most promising therapeutic candidates and its CDMO operations, which provide a revenue stream to support its development activities. The company is currently advancing two IL-17 programs within its NanoAb platform, including an intradermal psoriasis program. For this program, approximately €12 million in grant financing is under evaluation in Poland, which could significantly offset development costs if awarded.

In addition to its R&D progress, Scinai reported approximately $3.1 million in committed CDMO customer orders as of Aug. 16. The company continues to pursue approximately $5 million in CDMO revenue for 2026, subject to project execution, timing, revenue recognition, and additional business opportunities. This CDMO revenue is a key component of Scinai's strategy to create a sustainable financial foundation while it advances its pipeline.

The strategic focus on the NanoAb platform and CDMO growth is expected to enhance shareholder value by concentrating on areas with high potential and near-term revenue generation. By terminating the PC111 arrangement, Scinai avoids further investment in a program that may not have aligned with its core strategic priorities, allowing it to allocate resources more efficiently.

Scinai Immunotherapeutics is a biopharmaceutical company focused on developing innovative immunology therapies. The company is advancing a pipeline of therapeutic candidates licensed from the Max Planck Society and from PinCell S.r.l. In addition, Scinai owns Scinai Biopharma Services Ltd., a CDMO that provides development and manufacturing services to biotechnology and pharmaceutical companies through facilities in Jerusalem and Yavne, Israel.

The company's decision to refocus its R&D efforts is a prudent step in a competitive biotech landscape, where strategic prioritization is crucial for success. By concentrating on its NanoAb platform and CDMO services, Scinai aims to leverage its strengths and create multiple avenues for growth. The potential grant financing for the psoriasis program, if secured, would be a significant validation of the platform's promise.

Investors and stakeholders will be watching closely as Scinai executes this refined strategy, which seeks to balance innovative research with commercial viability. The company's ability to secure CDMO orders and advance its NanoAb programs will be key indicators of its future performance.